Brief: Gamida Cell Reports Opening to Enrollment of Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
01/06/2022 12:51
June 1 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL ANNOUNCES OPENING TO ENROLLMENT OF
COMPANY-SPONSORED
PHASE 1/2 STUDY OF NK CELL THERAPY CANDIDATE GDA-201
Source text for Eikon: ID:nBw9dMHSfa
Further company coverage: GMDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq